<p>隨着美國市場面臨波動的指數和人工智能泡沫的擔憂，道瓊斯工業平均指數最近創下歷史新高後回落，而以納斯達克為代表的科技股在更廣泛的經濟不確定性中承受壓力。在這個動態環境中，識別高增長科技股需要尋找那些展現出韌性和適應市場變化能力的公司，特別是那些能夠有效應對技術進步和投資者情緒的公司。</p>
<h3>美國十大高增長科技公司</h3>
<table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA 生物製藥</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.16%</td>
<td>29.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.17%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Atlassian</td>
<td>14.86%</td>
<td>53.82%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>46.09%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器的 75 只股票完整列表。</p>
<p>我們將查看篩選工具中一些最佳選擇。</p>
<h2>Annexon (ANNX)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Annexon, Inc. 是一家臨牀階段的生物製藥公司，專注於發現和開發與炎症相關的疾病藥物，市值為 7.4081 億美元。</p>
<p><strong>運營：</strong> Annexon, Inc. 專注於發現和開發針對炎症相關疾病的治療方案，目前沒有收入來源，因為它仍處於臨牀階段。</p>
<p>儘管目前尚未盈利，Annexon 正在經歷一個變革階段，獲得了大量資本注入和戰略研發投資，旨在扭轉其財務軌跡。最近通過股權融資籌集了近 7500 萬美元，該公司正在增強其資金儲備，以支持研究工作和潛在市場擴展。這一戰略舉措與他們 75.1% 的年收入增長率預期相一致，遠遠超過美國市場 10.6% 的增長預期。此外，Annexon 對創新的承諾顯而易見，他們預計在未來三年內將從虧損轉向盈利，這證明了他們在利用尖端技術實現可觀增長方面的潛力，儘管面臨高度競爭的行業。</p>
<ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Annexon 的動態。</li>
<li>瞭解 Annexon 的歷史表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0cf64f16-0068-4582-93ce-27b37ede180e/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0cf64f16-0068-4582-93ce-27b37ede180e/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 ANNX 收入和支出明細</p>
<h2>Savara (SVRA)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> Savara Inc. 是一家臨牀階段的生物製藥公司，專注於罕見呼吸疾病，市值為 16.7 億美元。</p>
<p><strong>運營：</strong> Savara Inc. 正在開發針對罕見呼吸疾病的治療方案，目前沒有報告的收入來源。該公司作為一家臨牀階段實體，專注於推進其產品管道，而不是產生即時銷售收入。</p>
<p>Savara 在近期專利批准和會議展示等一系列活動中展現了在高增長科技領域的韌性。該公司的戰略研發投資在其最新的罕見肺病治療創新中得到了體現，特別是 MOLBREEVI，該藥物已獲得全球多個衞生機構的多項認證。儘管財務表現面臨挑戰，淨虧損在九個月內擴大至 8660 萬美元，Savara 對通過技術推進醫療保健的承諾通過其積極的會議參與和總計約 1.3 億美元的重大股權融資得到了強調。這種方法不僅為他們的研究提供了資金，還使他們在生物技術領域的未來增長中佔據了有利位置，朝着盈利的方向發展。</p>
<ul>
<li>點擊這裏深入瞭解 Savara 的完整分析健康報告。</li>
<li>查看我們的歷史表現報告，以獲取 Savara 過去表現的見解。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown"/></p>
<p>截至 2025 年 12 月的 SVRA 收入和支出明細</p>
<h2>MNTN (MNTN)</h2>
<p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> MNTN, Inc. 運營一個專注於連接電視的績效營銷技術平台，市值為 9.2994 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過其互聯網軟件和服務部門產生收入，總計為 2.7281 億美元。</p>
<p>MNTN, Inc. 在科技領域展現出強勁的增長，特別是通過戰略整合和創新，例如與 Northbeam 的近期合作。這一合作通過將 MNTN 的績效電視廣告活動與 Northbeam 的營銷測量平台整合，提升了 MNTN 的廣告效果，在其測試階段顯示出 1.8 倍的營銷效率比率和 90% 的新網站訪問量，表明強勁的表現指標，可能推動未來的增長。此外，MNTN 推出的 QuickFrame AI——一個一體化視頻製作平台，突顯了其利用尖端技術簡化內容創作和分發的承諾，在廣告效率和效果上設定了新的標準。通過這些進展，MNTN 不僅在當前趨勢中獲益，還為在連接電視和數字廣告不斷演變的領域中保持持續影響力做好了準備。</p>
<ul>
<li>在我們的健康報告中更深入地瞭解 MNTN 的潛力。</li>
<li>探索歷史數據，以跟蹤 MNTN 在我們過去部分的表現。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5d48116-095f-4916-ab14-c10b219887fd/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1642" height="1048" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5d48116-095f-4916-ab14-c10b219887fd/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 MNTN 收益和收入增長</p>
<h2>總結</h2>
<ul>
<li>點擊開始探索其餘 72 只美國高增長科技和人工智能股票。</li>
<li>是這些公司的股東之一嗎？確保通過在 Simply Wall St 添加您的投資組合，及時獲取重大股票動態的提醒。</li>
<li>使用免費的 Simply Wall St 應用程序更智能地投資，提供全球每個股票市場的詳細見解。</li>
</ul>
<h2>對其他可能性感興趣？</h2>
<ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
<p><em>這篇文章由 Simply Wall St 撰寫，性質為一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
<p>用於國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人機器人。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

MRKR

ADMA生物制藥

PLTR

<p>美國市場正經歷波動的指數和對人工智能泡沫的擔憂，道瓊斯指數在創下歷史新高後回落。值得關注的高增長科技股包括 ADMA 生物製藥、Marker Therapeutics、Palantir Technologies、Workday、Circle Internet Group、Atlassian、RenovoRx、Zscaler、Duos Technologies Group 和 Procore Technologies。像 Annexon、Savara 和 MNTN 這樣的公司因其在科技領域的韌性和戰略增長而受到關注。這些公司正在進行重大研發投資和合作，以應對市場變化並推動未來增長</p>

<p>As the U.S. market grapples with fluctuating indices and AI bubble concerns, the Dow Jones Industrial Average recently hit an all-time high before retreating, while tech-heavy stocks like those in the Nasdaq face pressure amid broader economic uncertainties. In this dynamic environment, identifying high-growth tech stocks involves looking for companies that demonstrate resilience and adaptability to market shifts, particularly those that can navigate technological advancements and investor sentiment effectively.</p>
<div class="lb-trans"><p>隨着美國市場面臨波動的指數和人工智能泡沫的擔憂，道瓊斯工業平均指數最近創下歷史新高後回落，而以納斯達克為代表的科技股在更廣泛的經濟不確定性中承受壓力。在這個動態環境中，識別高增長科技股需要尋找那些展現出韌性和適應市場變化能力的公司，特別是那些能夠有效應對技術進步和投資者情緒的公司。</p>
</div><h3>Top 10 High Growth Tech Companies In The United States</h3>
<div class="lb-trans"><h3>美國十大高增長科技公司</h3>
</div><table>
<thead>
<tr>
<th>Name</th>
<th>Revenue Growth</th>
<th>Earnings Growth</th>
<th>Growth Rating</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA Biologics</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.16%</td>
<td>29.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.17%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Atlassian</td>
<td>14.86%</td>
<td>53.82%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>46.09%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>名稱</th>
<th>收入增長</th>
<th>盈利增長</th>
<th>增長評級</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADMA 生物製藥</td>
<td>20.12%</td>
<td>23.48%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Marker Therapeutics</td>
<td>75.24%</td>
<td>59.07%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Palantir Technologies</td>
<td>27.16%</td>
<td>29.97%</td>
<td>★★★★★★</td>
</tr>
<tr>
<td>Workday</td>
<td>11.17%</td>
<td>32.18%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Circle Internet Group</td>
<td>23.14%</td>
<td>84.30%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Atlassian</td>
<td>14.86%</td>
<td>53.82%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>RenovoRx</td>
<td>71.45%</td>
<td>71.45%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Zscaler</td>
<td>15.85%</td>
<td>46.09%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Duos Technologies Group</td>
<td>53.36%</td>
<td>152.11%</td>
<td>★★★★★☆</td>
</tr>
<tr>
<td>Procore Technologies</td>
<td>11.76%</td>
<td>116.48%</td>
<td>★★★★★☆</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 75 stocks from our US High Growth Tech and AI Stocks screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們美國高增長科技和人工智能股票篩選器的 75 只股票完整列表。</p>
</div><p>We're going to check out a few of the best picks from our screener tool.</p>
<div class="lb-trans"><p>我們將查看篩選工具中一些最佳選擇。</p>
</div><h2>Annexon (ANNX)</h2>
<div class="lb-trans"><h2>Annexon (ANNX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Annexon, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing medicines for inflammatory-related diseases, with a market cap of $740.81 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Annexon, Inc. 是一家臨牀階段的生物製藥公司，專注於發現和開發與炎症相關的疾病藥物，市值為 7.4081 億美元。</p>
</div><p><strong>Operations:</strong> Annexon, Inc. specializes in the discovery and development of treatments for inflammatory-related diseases without current revenue streams, as it remains in the clinical-stage phase.</p>
<div class="lb-trans"><p><strong>運營：</strong> Annexon, Inc. 專注於發現和開發針對炎症相關疾病的治療方案，目前沒有收入來源，因為它仍處於臨牀階段。</p>
</div><p>Annexon, despite its current unprofitability, is navigating through a transformative phase with significant capital influx and strategic R&amp;D investments aimed at reversing its financial trajectory. Recently raising nearly $75 million through equity offerings, the company is bolstering its war chest to fuel research endeavors and potential market expansions. This strategic move aligns with their impressive projected annual revenue growth rate of 75.1%, starkly outpacing the broader U.S. market's growth expectation of 10.6%. Furthermore, Annexon's commitment to innovation is evident as they anticipate transitioning from losses to profitability within the next three years—a testament to their potential in harnessing cutting-edge technologies for substantial growth amidst a highly competitive sector.</p>
<div class="lb-trans"><p>儘管目前尚未盈利，Annexon 正在經歷一個變革階段，獲得了大量資本注入和戰略研發投資，旨在扭轉其財務軌跡。最近通過股權融資籌集了近 7500 萬美元，該公司正在增強其資金儲備，以支持研究工作和潛在市場擴展。這一戰略舉措與他們 75.1% 的年收入增長率預期相一致，遠遠超過美國市場 10.6% 的增長預期。此外，Annexon 對創新的承諾顯而易見，他們預計在未來三年內將從虧損轉向盈利，這證明了他們在利用尖端技術實現可觀增長方面的潛力，儘管面臨高度競爭的行業。</p>
</div><ul>
<li>Click here and access our complete health analysis report to understand the dynamics of Annexon.</li>
<li>Learn about Annexon's historical performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整健康分析報告，以瞭解 Annexon 的動態。</li>
<li>瞭解 Annexon 的歷史表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/0cf64f16-0068-4582-93ce-27b37ede180e/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/0cf64f16-0068-4582-93ce-27b37ede180e/chart/revenue-and-expenses-breakdown"/></p>
<p>ANNX Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 ANNX 收入和支出明細</p>
</div><h2>Savara (SVRA)</h2>
<div class="lb-trans"><h2>Savara (SVRA)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> Savara Inc. is a clinical-stage biopharmaceutical company concentrating on rare respiratory diseases, with a market cap of $1.67 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Savara Inc. 是一家臨牀階段的生物製藥公司，專注於罕見呼吸疾病，市值為 16.7 億美元。</p>
</div><p><strong>Operations:</strong> Savara Inc. is engaged in developing therapies for rare respiratory diseases, with no reported revenue streams currently available. The company operates as a clinical-stage entity, focusing on advancing its pipeline rather than generating immediate sales revenue.</p>
<div class="lb-trans"><p><strong>運營：</strong> Savara Inc. 正在開發針對罕見呼吸疾病的治療方案，目前沒有報告的收入來源。該公司作為一家臨牀階段實體，專注於推進其產品管道，而不是產生即時銷售收入。</p>
</div><p>Savara, amid a flurry of activity including recent patent approvals and conference presentations, exemplifies resilience in the high-growth tech sector. The company's strategic R&amp;D investments are evident with its latest innovations in treatments for rare lung diseases, notably MOLBREEVI which has received multiple designations from health authorities globally. Despite a challenging financial performance with a net loss widening to $86.6 million over nine months, Savara's commitment to advancing healthcare through technology is underscored by an aggressive conference presence and significant equity offerings totaling approximately $130 million. This approach not only fuels their research but also positions them favorably within the biotech landscape for potential future growth as they navigate towards profitability.</p>
<div class="lb-trans"><p>Savara 在近期專利批准和會議展示等一系列活動中展現了在高增長科技領域的韌性。該公司的戰略研發投資在其最新的罕見肺病治療創新中得到了體現，特別是 MOLBREEVI，該藥物已獲得全球多個衞生機構的多項認證。儘管財務表現面臨挑戰，淨虧損在九個月內擴大至 8660 萬美元，Savara 對通過技術推進醫療保健的承諾通過其積極的會議參與和總計約 1.3 億美元的重大股權融資得到了強調。這種方法不僅為他們的研究提供了資金，還使他們在生物技術領域的未來增長中佔據了有利位置，朝着盈利的方向發展。</p>
</div><ul>
<li>Delve into the full analysis health report here for a deeper understanding of Savara.</li>
<li>Review our historical performance report to gain insights into Savara's's past performance.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏深入瞭解 Savara 的完整分析健康報告。</li>
<li>查看我們的歷史表現報告，以獲取 Savara 過去表現的見解。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown" alt="" original-src="https://images.simplywall.st/company/da6f666a-85e8-4cd7-a251-639ab8769d33/chart/revenue-and-expenses-breakdown"/></p>
<p>SVRA Revenue and Expenses Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 SVRA 收入和支出明細</p>
</div><h2>MNTN (MNTN)</h2>
<div class="lb-trans"><h2>MNTN (MNTN)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 增長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> MNTN, Inc. operates a technology platform focused on performance marketing for Connected TV and has a market cap of $929.94 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> MNTN, Inc. 運營一個專注於連接電視的績效營銷技術平台，市值為 9.2994 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its Internet Software &amp; Services segment, totaling $272.81 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其互聯網軟件和服務部門產生收入，總計為 2.7281 億美元。</p>
</div><p>MNTN, Inc. is demonstrating robust growth in the tech sector, particularly through strategic integrations and innovations like its recent partnership with Northbeam. This collaboration enhances MNTN's Performance TV campaigns by integrating them with Northbeam's marketing measurement platform, which during its beta period showed a 1.8x marketing efficiency ratio and 90% new site visits, indicating strong performance metrics that could drive future growth. Additionally, MNTN's introduction of QuickFrame AI—an all-in-one video-production platform—underscores its commitment to leveraging cutting-edge technology to streamline content creation and distribution across various media channels, setting a new standard in advertising efficiency and effectiveness. With these advancements, MNTN is not only capitalizing on current trends but also positioning itself for sustained influence in the evolving landscape of Connected TV and digital advertising.</p>
<div class="lb-trans"><p>MNTN, Inc. 在科技領域展現出強勁的增長，特別是通過戰略整合和創新，例如與 Northbeam 的近期合作。這一合作通過將 MNTN 的績效電視廣告活動與 Northbeam 的營銷測量平台整合，提升了 MNTN 的廣告效果，在其測試階段顯示出 1.8 倍的營銷效率比率和 90% 的新網站訪問量，表明強勁的表現指標，可能推動未來的增長。此外，MNTN 推出的 QuickFrame AI——一個一體化視頻製作平台，突顯了其利用尖端技術簡化內容創作和分發的承諾，在廣告效率和效果上設定了新的標準。通過這些進展，MNTN 不僅在當前趨勢中獲益，還為在連接電視和數字廣告不斷演變的領域中保持持續影響力做好了準備。</p>
</div><ul>
<li>Take a closer look at MNTN's potential here in our health report.</li>
<li>Explore historical data to track MNTN's performance over time in our Past section.</li>
</ul>
<div class="lb-trans"><ul>
<li>在我們的健康報告中更深入地瞭解 MNTN 的潛力。</li>
<li>探索歷史數據，以跟蹤 MNTN 在我們過去部分的表現。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/d5d48116-095f-4916-ab14-c10b219887fd/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/d5d48116-095f-4916-ab14-c10b219887fd/chart/earnings-and-revenue-growth"/></p>
<p>MNTN Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 MNTN 收益和收入增長</p>
</div><h2>Summing It All Up</h2>
<div class="lb-trans"><h2>總結</h2>
</div><ul>
<li>Click through to start exploring the rest of the 72 US High Growth Tech and AI Stocks now.</li>
<li>Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.</li>
<li>Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊開始探索其餘 72 只美國高增長科技和人工智能股票。</li>
<li>是這些公司的股東之一嗎？確保通過在 Simply Wall St 添加您的投資組合，及時獲取重大股票動態的提醒。</li>
<li>使用免費的 Simply Wall St 應用程序更智能地投資，提供全球每個股票市場的詳細見解。</li>
</ul>
</div><h2>Interested In Other Possibilities?</h2>
<div class="lb-trans"><h2>對其他可能性感興趣？</h2>
</div><ul>
<li>Explore high-performing small cap companies that haven't yet garnered significant analyst attention.</li>
<li>Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.</li>
<li>Find companies with promising cash flow potential yet trading below their fair value.</li>
</ul>
<div class="lb-trans"><ul>
<li>探索尚未獲得顯著分析師關注的高表現小型公司。</li>
<li>用顯示強勁增長潛力的公司來充實您的投資組合，這些公司得到了分析師和管理層的樂觀展望支持。</li>
<li>尋找現金流潛力良好但交易價格低於其公允價值的公司。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>這篇文章由 Simply Wall St 撰寫，性質為一般性。<strong>我們提供基於歷史數據和分析師預測的評論，採用無偏見的方法，我們的文章並不構成財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>用於國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人機器人。它是完全自主的塔，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

3 High Growth Tech Stocks To Watch In The US Market

- 美國市場面臨波動的指數和 AI 泡沫擔憂，道瓊斯工業平均指數創下歷史新高後回落。  
- 高增長科技公司如 Annexon 和 Savara 專注於研發，儘管當前無收入，仍展現出強勁的增長潛力。  
- MNTN 通過技術整合和創新，提升廣告效率，顯示出在數字廣告領域的持續影響力。  

美國市場上值得關注的三隻高增長科技股票